Sanofi's Jevtana still too expensive for NICE, despite end-of-life credentials rethink
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, maintains that Sanofi-Aventis’ docetaxel follow-on Jevtana (cabazitaxel) is too costly for treating prostate cancer patients on the National Health Service. Final negative draft guidance comes even though the institute changed its mind and recognised that the drug does in fact meet NICE's end-of-life criteria that gives it more scope to consider expensive drugs.
You may also be interested in...
Real World Data Failed To Impress Kaftrio’s European Reviewers
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Australian Industry Maps Path To Better Use Of Real World Evidence
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
Need a specific report? 1000+ reports available
Buy Reports